Hari Kumar appointed CEO of Panmira
This article was originally published in Scrip
Panmira Pharmaceuticals, a small molecule pharmaceutical company focused on novel therapies for inflammatory diseases, has appointed Dr Hari Kumar CEO. Until recently, Dr Kumar served as chief business officer of Amira Pharmaceuticals, where he led the transaction with Bristol-Myers Squibb for the sale of Amira's fibrosis programme.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.